The report provides a detailed analysis essential for establishing a capmatinib production plant. It encompasses all critical aspects necessary for capmatinib production, including the cost of capmatinib production, capmatinib plant cost, capmatinib production costs, and the overall capmatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a capmatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Capmatinib is a targeted anticancer medicine mainly used in the treatment of certain types of lung cancer. It is primarily prescribed for patients with non-small cell lung cancer that has specific genetic changes known as MET exon 14 skipping mutations. The drug works by blocking the MET receptor, which helps stop the growth and spread of cancer cells. It helps slow the growth of cancer cells and improve breathing problems linked to lung tumours. It finds its main application in patients whose cancer has spread to other parts of the body or cannot be removed by surgery. In some cases, it helps manage symptoms like persistent cough or chest discomfort by reducing tumour size. Moreover, it is used as part of personalised cancer therapy based on genetic testing results.It is also used as a reference drug in research to explore its use in combination with other cancer medicines to improve treatment results in the future.
The market for capmatinib is primarily driven by its demand as a potential antineoplastic agent for the treatment of certain lung cancers that carry a specific MET gene change. Its application as a drug for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a mutation also fuels its demand in the pharmaceutical industry. Its application as part of personalised cancer therapy to slow disease progression and improve patient outcomes further boosts its demand in the medical and healthcare sectors.
Its ability to help patients whose cancer has spread or does not respond to standard therapies further boosts its demand in oncology clinics. Industrial capmatinib procurement is shaped by the cost and steady availability of speciality raw materials, along with strict regulatory rules and quality checks required for precision cancer medicines. Moreover, progress in synthesis methods, stable supplier networks, safe handling procedures, and well-managed distribution systems also influence procurement strategies globally.
Raw Material for Capmatinib Production
According to the capmatinib production plant project report, the major raw materials for capmatinib production include 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b]triazin-2-yl)benzoic acid, PyBOP (benzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate), methylamine, and triethylamine.
Production Process of Capmatinib
The extensive capmatinib production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of capmatinib begins with dissolving 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b]triazin-2-yl)benzoic acid and PyBOP (benzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate) coupling agent in DMF, followed by slowly adding a methylamine solution in THF at room temperature. Then, the mixture is gently heated to 30 degrees Celsius to form a clear mixture. Further, triethylamine is added, and the reaction mixture is stirred for a few hours until completion. Then, water is introduced to precipitate the product, which is cooled in an ice bath, filtered, and washed. The wet solid gets resuspended in a water-acetonitrile mix, stirred, refiltered, washed again with water and acetonitrile, and finally dried in a vacuum oven to obtain Capmatinib as a yellow powder.
Capmatinib appears as a pale yellow to light yellow powder in its hydrochloride salt form, which exhibits a needle-shaped crystalline morphology. The molecular formula of the free base is C23H17FN6O, and its molar mass is 412.43 g/mol. It is slightly soluble in acidic aqueous solutions at pH 1 and 2, and it is classified as a low-solubility, moderate-permeability compound under the Biopharmaceutics Classification System. It has a density of around 1.4 g/cm³. The melting point of the compound is above 250 degrees Celsius. It is marketed under the brand name Tabrecta. The compound is known to cause photosensitivity, and patients are advised to use sunscreen and protective clothing to limit ultraviolet exposure during treatment. Extended use of this substance may cause serious adverse effects such as interstitial lung disease, pneumonitis, hepatotoxicity, peripheral edema, nausea, and embryo-fetal toxicity.
